Post-Workshop Evaluation Form

More documents

Recommendations

Info

5. _______________ can be defined as administering medications used in the treatment of HIV to "high risk" HIV-negative individuals in hopes of preventing transmission of the virus. a) Proactive Highly Active Antiretroviral Treatment b) <strong>Post</strong> Exposure Prophylaxis c) Pre Exposure Prophylaxis d) Harm Reduction 6. All of the following would make a drug a good candidate for Pre Exposure Prophylaxis EXCEPT: a) Easy to use: Only one pill required per day (maybe less). b) Safe: Few side effects in HIV-positive people. c) Sedative: Makes a person sleepy so they don’t engage in risky behaviours d) Powerful: Stays in the bloodstream a long time. e) Unique resistance profiles: If resistance develops, other treatment options still exist. 7. A vaccine works by: a) teaching the body to recognize an infectious agent b) laying dormant, then attacking an infectious agent once it invades the body c) helping the body remain healthy despite an infection (keeps it in check) d) layering cells in protective armour 8. Clinical trials are: a) A process of testing products in humans b) A process of testing products in animals c) A process of testing products in the laboratory d) A process of administering products in clinics 9. “Informed consent” in clinical trials is: a) A group education process that includes signing an agreement with other potential volunteers in the trial b) The continuous process of explaining to volunteers all information about a clinical trial or study to ensure that they understand and independently sign an agreement before joining c) The process of informing a participant about a trial d) The consent given by volunteers to receive information about a specific issue 2
10. Effectiveness of an NPT refers to: a) The cost of producing the NPT compared to the profit from the NPT b) The ability of a NPT to reduce incidence of the disease in the community c) The ability of a NPT to produce an immune response against the disease d) The ability of a NPT to produce an immune response in the shortest time possible 11. Efficacy of a NPT refers to: a) The ability of the NPT to prevent infection or disease in the trial population b) The ability of the NPT to protect against diseases other than the one it was intended for c) The ability of the NPT to protect against the disease 100% of the time d) The ability of the NPT to produce quick results 12. Randomisation in clinical trials is: a) A process of choosing at random which participants will get the candidate product or the placebo b) A random process of choosing countries where the NPT trial is going to be conducted c) A random process of selecting people from the population to be part of the NPT trial d) When a participant makes a choice to belong to either the placebo group or the candidate product group 13. A placebo is: a) A place where the NPT is being tested in animals b) A substance that is given to volunteers to reduce potential side effects c) A harmless, inactive substance that resembles the candidate product in appearance d) A chemical substance used to determine when someone was infected by HIV 14. The main objective of a Phase I clinical trial is to find out if the candidate product: a) Is safe b) Causes an immune response c) Protects against infection or disease d) Causes disease 15. The main objective of Phase III clinical trial is to find out if the candidate product: a) Is safe b) Provokes an immune response c) Protects against infection or disease d) Causes disease 3
Page 1: Post-Workshop Questionnaire Beyond

Post-Workshop Evaluation Form

Create successful ePaper yourself

Delete template?

Save as template?